Christoph Westphal
Manager @ Longwood Fund
Boston, United States
Christoph Westphal is a Series A investor at Longwood Fund in Boston focused on Biotechnology and Therapeutics. Christoph Westphal is the Founder of DEM BioPharma. He previously worked at Sirtris Pharmaceuticals as a CEO. Christoph Westphal attended Harvard Medical School.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Christoph Westphal invests in
Stages Christoph Westphal invests in
Countries Christoph Westphal invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (73%)
- Therapeutics 5 (45%)
- Life Science 3 (27%)
- Pharmaceutical 3 (27%)
- Medical 1 (9%)
Stage
- Series A 4 (36%)
- Series B 3 (27%)
- Seed 1 (9%)
- Series D 1 (9%)
- Funding Round 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $41M / Series A / Apr 09, 2025 | ||
| Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $31M / Seed / Aug 01, 2023 | ||
| DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints. | $70M / Series A / Jun 23, 2022 | ||
| Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $58M / Series B / Aug 18, 2021 | ||
| ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. | $50M / Series A / Jun 23, 2021 | ||
| ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. | $17M / Venture - Series Unknown / Feb 17, 2021 | ||
| Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival. | $35M / Series D / Oct 29, 2013 | ||
| Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $18.9M / Series B / Jan 12, 2004 | ||
| Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $9.3M / Series A / Jul 26, 2002 | ||
| Advion is a global company that offers a variety of systems and consumables for life science research. Its clientele is comprised of pharmaceutical companies, government life science research agencies, and universities. Advion provides a diverse portfolio of microfluidic and mass spec-based products for the life science industry. It was founded in1993. The company is headquartered in New York, United States. | $15M / Series B / May 09, 2002 | ||
| See all 11 investments → | |||
Co-Investors
About Longwood Fund
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Longwood Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aleks Radovic-Moreno
Partner
|
|||
John McCabe
Operating Partner
|
|||
|
Christoph Westphal
Manager
|
|||
David Donabedian
Executive Partner
|
|||
David Donabedian, PhD
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christoph Westphal invest in?
Christoph Westphal invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christoph Westphal?
Public channels for Christoph Westphal include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christoph Westphal last invest?
The most recent investment recorded for Christoph Westphal closed in Apr 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
